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abstract
CONTEXT: Sentinel node (SN) biopsy has changed the surgical
treatment of malignant melanoma. The literature has emphasized
the importance of gamma probe detection (GPD) of the SN.
OBJECTIVE: Our objective was to evaluate the efficacy of patent
blue dye (PBD) and GPD for SN biopsy in different lymphatic basins.
DESIGN: Patients with cutaneous malignant melanoma in stages I
and II were submitted to biopsy of the SN, identified by PBD and
GPD, as part of a research project.
SETTING: Patients were seen at Hospital São Paulo by a
multidisciplinary group (Plastic Surgery Tumor Branch, Nuclear
Medicine and Pathology).
PATIENTS: 64 patients with localized malignant melanoma were
studied. The median age was 46.5 years. The primary tumor was
located in the neck, trunk or extremities.
INTERVENTIONS: Preoperative lymphoscintigraphy, lymphatic
mapping with PBD and intraoperative GPD was performed on all
patients. The SN was examined by conventional and immunohis-
tochemical staining. If the SN was not found or contained
micrometastases, only complete lymphadenectomy was performed.
MAIN MEASUREMENTS: The SN was identified by PBD if it was
blue-stained, and by GPD if demonstrated activity five times greater
than the adipose tissue of the neighborhood.
RESULTS: Seventy lymphatic basins were explored.
Lymphoscintigraphy showed ambiguous drainage in 7 patients. GPD
identified the SN in 68 basins (97%) and PBD in 53 (76%). PBD and
GPD identified SN in 100% of the inguinal basins. For the remaining
basins both techniques were complementary. A metastatic SN was
found in 10 basins. Three patients with negative SN had recurrence
(median follow-up = 11 months).
CONCLUSION: Although both GPD and PBD are useful and comple-
mentary, PBD alone identified the SN in 100% of the inguinal
lymphatic basins.
KEY WORDS: Sentinel node. Lymphoscintigraphy. Gamma detec-
tion. Lymphatic mapping.
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INTRODUCTION
Surgical treatment of regional lymph nodes in
cutaneous malignant melanoma stage I and II is still
controversial.1-4 The main problem is to characterize
which patients must have lymphadenectomy. In 13.3%
of stage I and 20% of stage II patients, clinically hidden
lymph node metastases are removed at an early stage
with elective lymph node dissection. In the remaining
cases, no tumor is found in the lymph nodes and these
patients receive excessive treatment and are submitted
to the risk of postoperative complications.5-11 Balch et al.
characterized a subgroup of patients under 60 years old
with tumor thickness of 1-4 mm who benefited from elec-
tive lymph node dissection.12,13
The concept of sentinel lymph node (SN), the first
node in the lymphatic basin that drains the area of the
primary tumor, has changed the surgical approach in
melanoma patients. This technique involves four pro-
cedures: pre-operative lymphoscintigraphy, intraopera-
tive lymphatic mapping, intraoperative gamma-probe
detection (GPD) and histopathology. Pre-operative
lymphoscintigraphy identifies the lymphatic basins at
risk for metastatic disease, anomalous drainage and in-
transit metastasis. Intraoperative lymphatic mapping
with a vital dye (we have used patent blue dye, PBD)
anatomically and functionally mimics the lymphatic
spread of neoplastic cells from the primary site to the
lymphatic basin. Blue staining of lymphatic vessels al-
lows identification of the SN, as initially demonstrated
by Morton et al.14,15
GPD allows better localization of SN with less
extensive dissection.16 The SN is submitted to conven-
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tional histopathological examination (hematoxylin-
eosin) and immunohistochemical staining with HMB
45 antigen and S-100 protein. Only patients with positive
SN are submitted to complete lymphadenectomy.17,18
The accuracy of SN in predicting the histopathological
status of the lymphatic basin has been confirmed by
several groups around the world.19-23
SN biopsy has changed surgical treatment of
melanoma. The literature has emphasized the impor-
tance of GPD in the SN biopsy. Before introducing GPD
in our practice, we had used PBD alone with very good
results for lymph nodes of the inguinal region. Our
objective was to evaluate the efficacy of PBD and GPD
in the SN biopsy of different lymphatic basins.
The role of PBD and GPD in the identification of
the SN in different lymphatic basins of cutaneous
malignant melanoma patients was studied.
METHODS
Setting. Patients were treated at Hospital São
Paulo of the Universidade Federal de São Paulo/Escola
Paulista de Medicina (UNIFESP/EPM) by a multi-
disciplinary group (Plastic Surgery Tumor Branch,
Nuclear Medicine and Pathology).
Patients. Sixty-four patients with clinically localized
malignant melanoma with Breslow thickness equal to or
greater than 0.8 mm were enrolled. Excision biopsy of the
primary tumor was performed at most 60 days before the
sentinel lymph node biopsy. Informed consent was obtained
from all patients. Of the 64 patients, 31 were men and 33
women. The median age was 46.5 years old (range, 18-81
years old). The median thickness of the primary tumor was
1.3 mm (range, 0.8-7.0 mm). Thirty-eight patients were at
clinical stage IB, 19 IIA and 7 IIB. The primary sites were the
neck,2 trunk32 and extremities.30 Clinicopathologically, there
were 4 accrual melanoma, 36 superficial spreading
melanoma and 24 nodular melanoma. Ulceration was
present in 9 cases (Table 1).
Interventions. Before operation, all patients un-
derwent lymphoscintigraphy to characterize the lym-
phatic basin of drainage and to localize the SN. A dose
of 250 microcurie (99mTC-dextran 500) was injected
intradermally at 2 to 4 points around the biopsy scar
or the melanoma lesion if still present.
Immediately afterwards, dynamic images were
obtained to visualize the lymphatic drainage. Dynamic
acquisition of images continued for a minimum of 20
min to a maximum of 45 min. Anterior and lateral static
images, using a dual-head gamma camera (Eucint He-
lix HR), were obtained until the SN was found. The last
image was obtained after 2 hours. These images were
complemented by oblique views whenever the injec-
tion site could obscure the SN. The position of the SN
was then marked on the skin.
In the operating room, a similar injection of
99mTC-dextran was given for GPD. A convenient site for
incision was confirmed and determined using a
Neoprobe 1500 device as a gamma probe detector
(Columbus, OH). To consider a node as an SN it had
to demonstrate at least 5 times more activity than the
adipose tissue of the neighborhood.
Intraoperative lymphatic mapping with patent blue
dye (PBD) was performed according to the technique
described by Morton et al.12 A small incision was made,
and the subcutaneous tissue was explored in the search
for a blue-stained lymphatic channel. The channel was
carefully dissected down to the blue-stained SN.
After the biopsy was performed, the SN (ex vivo)
and the operative field were checked by probe. The
excised SN was sent for pathological examination,
using a paraffin hematoxylin-eosin section and immu-
nohistochemical staining with S-100 protein and HMB-
45 antigen. Only when micrometastases were present
was a formal regional lymph node dissection
performed. The average follow-up for this group of
patients was 11 months (range, 1 - 25 months).
Main measurement. The SN was identified by PBD
if it was blue-stained and by GPD if it demonstrated at
least five times more activity than the adipose tissue
around it.
RESULTS
Seventy lymphatic basins were explored.
Lymphoscintigraphy showed ambiguous drainage in 7
patients. The distribution of the basins were: axillary,35
inguinal29 and cervical.6 In all cases PBD and GPD were
performed, identifying a total of 98 SN (1.4 SN per lym-
phatic basin). GPD identified the SN in 68 basins (97%)
Table 1. General patient characteristics
Sex 31 Men : 33 Women
Age 18 - 81 years (median = 46.5 years)
Breslow 0.8 - 7 mm (median = 1.3 mm)
Primary site
Neck 2
Trunk 32
Members 30
Clinical Stage
IB 38
IIA 19
IIB 7
Histopathological type
Superficial spreading 36
Nodular 24
Accrual 4
Ulceration 9
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and PBD in 53 basins (76%). In the axillary region, GPD
identified SN in 34 basins (97%) and PBD in 22 basins
(63%). In cervical basins, GPD identified SN in 5 (83%)
and PBD in 2 (33%). For the 29 inguinal basins, both GPD
and PBD identified 100% of the SN (Table 2).
A tumor-positive SN was found in 10 patients (8
on permanent sections and 2 on immunohistochemis-
try only). Regional node dissection was performed on
all 10 patients with tumor-containing SN. In addition
to the SN, other involved nodes were found in three
patients. Although with a short follow-up (11 months),
three patients with a tumor-negative SN biopsy had a
relapse: one in the same basin, another developed in-
transit metastasis and the third had liver metastasis
(Breslow = 1.2 mm, 2.4 mm and 2.3 mm, respectively).
Postoperative complications were seen in four patients,
which were clinically treated (wound infection,
hematoma and seroma).
DISCUSSION
The SN procedure appears to be a reliable
method for regional location microstaging of mela-
noma patients with clinically hidden lymph node
metastases. The pathological status of SN is the most
important prognostic factor for tumor recurrence.24,25
When using only PBD, the literature has regis-
tered a lower identification rate for the SN (85%) than
with GPD (98-100%).26-29 Similar data were obtained in
our study (PBD = 76% and GPD = 97%). Subgroup
analysis of the basins showed that GPD and PBD iden-
tified 100% of the inguinal SN. For the remaining
basins (axillary and cervical), GPD and PBD were
complementary, but GPD identified more SN than PBD.
Lymphoscintigraphy had a crucial role in localizing the
SN basin and allowing skin localization of the SN,
especially in the inguinal region.
Some authors have questioned whether there
is any role for PBD in the SN biopsy,27 emphasizing
the role of GPD in the outpatient clinic. Others indi-
cate PBD as a standard procedure.30 Our data showed
that PBD alone is a very good technique for the in-
guinal SN, posing a different question: is intra-opera-
tive gamma probe detection really necessary for
inguinal sentinel lymph node biopsy? PBD simplifies
the procedure, can be done without an intraoperative
gamma detection device, and improves the cost /
benefit relationship.
Three patients with tumor-negative SN biopsy
had relapses. Perhaps a more powerful method for
evaluating the SN status would be able to identify
hidden micrometastases in those negative SN.
We are introducing detection of m-RNA
thyrosinase in the SN by the reverse transcriptase
polymerase chain reaction (RT-PCR). The sentinel node
biopsy technique will contribute to obtaining better
knowledge of the natural history of melanoma cell
dissemination.
Table 2. Percentage of SN identification
by PBD and GPD techniques for lymphatic basins
Technique Inguinal (29) axillary (35) Cervical (6) Total of basins (70)
PBD 100% 63% 33% 76% GPD
100% 97% 83% 97%
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resumo
CONTEXTO: A biópsia de linfonodo sentinela (LS) mudou a abordagem
cirúrgica do melanoma maligno. A literatura tem enfatizado a
importância da detecção gama intra-operatória (DG) do LS.
OBJETIVO: Nosso objetivo é avaliar a eficácia do corante azul
patente (AP) e da DG na biópsia de LS em diferentes bases linfáticas.
TIPO DE ESTUDO: Pacientes portadores de melanoma maligno
cutâneo foram submetidos à biópsia do LS, usando AP e DG como
parte de um projeto de pesquisa.
LOCAL: Hospital São Paulo, grupo multidisciplinar (cirurgião
oncológico, médico nuclear e patologista).
PACIENTES: Foram estudados 64 pacientes portadores de melanoma
maligno localizado, com idade mediana de 46,5 anos. O sítio
primário estava localizado no pescoço, tronco e nos membros.
INTERVENÇÕES: Linfocintilografia pré-operatória, mapeamento
linfático com AP e DG foram realizados em todos os pacientes. O LS
foi examinado por histopatologia convencional e imunohistoquímica.
Quando o LS não foi encontrado ou continha micrometástases,
linfadenectomia completa da base linfática foi realizada.
VARIÁVEIS ESTUDADAS: O LS foi considerado como identificado
pelo AP se corado em azul e pela DG quando demonstrou pelo
menos 5 vezes mais atividade do que o tecido gorduroso vizinho.
RESULTADOS: Foram exploradas 70 bases linfáticas. A linfocintilografia
mostrou drenagem ambígua em 7 pacientes. DG identificou o LS em
68 bases linfáticas (97%) e o AP o fez em 53 bases (76%). Os dois
métodos identificaram separadamente 100% dos LS inguinais. Nas
demais bases, as técnicas foram complementares. O LS estava invadido
por células tumorais em 10 bases. Três pacientes com LS negativo
apresentaram recorrência (seguimento mediano de 11 meses).
CONCLUSÃO: Embora o emprego de AP e GP na pesquisa de LS
sejam complementares, o AP demonstrou ser um método suficiente
para a localização do LS inguinal.
PALAVRAS-CHAVE: Linfonodo sentinela. Linfocintilografia. detecção
gama. Mapeamento linfático.
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